tbuckley/cabot-search huggingface dataset:
Postservice mortality among Vietnam veterans. The Centers for Disease Control Vietnam Experience Study
Journal: JAMA (1987)

The postservice mortality (through December 1983) of a cohort of 9324 US Army veterans who served in Vietnam was compared with that of 8989 Vietnam-era Army veterans who served in Korea, Germany, or the United States. Over the entire follow-up period, total mortality in Vietnam veterans was 17% higher than for other veterans. The excess mortality occurred mainly in the first five years after discharge from active duty (rate ratio, 1.45; 95% confidence interval, 1.08 to 1.96) and involved motor vehicle accidents, suicide, homicide, and accidental poisonings. Thereafter, mortality among Vietnam veterans was similar to that of other Vietnam-era veterans, except for drug-related deaths, which continued to be elevated. An unexpected finding was a deficit in deaths from diseases of the circulatory system among Vietnam veterans. The excess in postservice mortality due to external causes among Vietnam veterans is similar to that found among men returning from combat areas after World War II and the Korean War.
Medical News
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE "PHOSPHOCREATINE" OF MUSCLE
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recent Trends in Mortality Rates for Four Major Cancers, by Sex and Race/Ethnicity--United States, 1990-1998
Journal: JAMA (2002)

In 1998, 53% of all cancer-related deaths in the United States were associated with four sites: lung/bronchus, colon/rectum, prostate, and female breast. Cancer-related death does not affect racial/ethnic populations similarly. In 1996, the National Cancer Institute (NCI) published cancer incidence and death rates during 1988-1992 in 10 categories of race/ethnicity. To examine trends during 1990-1998 in annual death rates for the four major cancers by sex and race/ethnicity (i.e., blacks, whites, Hispanics, American Indians/Alaska Natives [AI/ANs], and Asians/Pacific Islanders [APIs]), CDC analyzed data from the National Center for Health Statistics' National Vital Statistics System. This report summarizes the results of that analysis, which indicated that, except for lung cancer in women and lung, colorectal, and breast cancer in AI/ANs, trends in death rates from these cancers have generally declined. But the rates remained high for blacks, have not decreased equally among all populations, and have increased in certain instances. Continuing research and prevention efforts are needed to reach high-risk and underserved populations and to understand the reasons for differences in cancer mortality among racial/ethnic populations.
Nomenclature Morass
Authors: Lester C. Mark
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Blood, New York
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunopathology
Authors: Thomas J. Gill
Journal: JAMA (1977)

A REQUEST by the American Board of Pathology to develop special competence certification in immunopathology was not acted on favorably by the Committee on Certification and Recertification of the American Board of Medical Specialties. The committee gave as its reason for this action that in their opinion, immunopathology was not a truly developing field of fundamental knowledge. They also stated that they thought that the field was too techniqueoriented. Furthermore, they indicated that they did not favor further proliferation of the special competence certificates of any kind. It is our purpose to emphasize the investment that pathology, as a scientific discipline, has made in immunopathology and the contributions that it has made to modern basic immunologic knowledge. It also includes results from two recent surveys that indicate the scope of developments in this field at present and thus the timeliness of the special competence recognition. The surveys indicate that there
Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe).
Journal: Diabetes Care (1999)

OBJECTIVE: To evaluate the prevalence of diabetes and the risk of death in older European men and women aged between 60 and 79 years at baseline using the new American Diabetes Association diagnostic criteria for diabetes. RESEARCH DESIGN AND METHODS: The analysis involved existing population-based European studies from the DECODE Study Group (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) and involved baseline measures of fasting and 2-h glucose concentrations after a 75-g oral glucose tolerance test (OGTT) and follow-up to determine deaths. This analysis included 4,032 men and 2,207 women who were not previously known to have diabetes and 383 men and 319 women who had established diabetes. RESULTS: More than half of the diabetic subjects had already been diagnosed, one sixth had a fasting hyperglycemia &amp;gt; or = 7.8 mmol/l (140 mg/dl), one-sixth had a fasting glucose level of 7.0-7.8 mmol/l (126-140 mg/dl), and one-sixth had an isolated postchallenge hyperglycemia (fasting glucose &amp;lt; 7.0 mmol/l and 2-h glucose &amp;gt; or = 11.1 mmol/l [200 g/dl]). Compared with non-diabetic subjects, the hazard ratios for death in diabetic subjects were close to 2 and did not differ significantly according to the method of diagnosis of diabetes, age-group, or sex. CONCLUSIONS: One-third of the older diabetic subjects who were undiagnosed at baseline had isolated postchallenge hyperglycemia. OGTT screening of the subjects with impaired fasting glucose (6.1-6.9 mmol/l) would reduce this fraction by half. The group with isolated postchallenge hyperglycemia had an elevated risk of mortality similar to that of other diabetic subjects.
BRAZIL
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Total tumor burden as predictive tool of response and survival of patients with metastatic melanoma treated with nivolumab.
Authors: Rafael Vanin de Moraes, Bianca Salgado Boneti, Milton Jose De Barros E. Silva, Vladmir Claudio Cordeiro De Lima
Journal: Journal of Clinical Oncology (2017)

e21022 Background: Nivolumab (NIVO) has shown increased results either in objective response rate (ORR), progression free survival (PFS) and overall survival (OS), which have completely changed the treatment of patients with metastatic melanoma (MM). Tools to guide selection of patients are absent Methods: This is a retrospective, observational, single-center study. The TBT was calculated considering the sum of the largest diameter of all measurable lesions and the smallest diameter of lymph nodes affected Results: 54 patients with histologiacally confirmed mm were included in the protocol (OCT/14-may/16). Patients had a median age of 61 years (22-86 years), 58% were male, and 73% of tumor were located in the skin. 42% had ECOG 1, 72% had M1c, and 36% had LDH over the upper limit of normality (ULN). 34% had the mutation of the BRAF (half of them treated with IBRAF). About 75% had no prior benefit with anti-CTLA4 and 21% of the population had brain metastases. The median follow-up was 11.1 months and the median NIVO doses was 10 cycles. The ORR was 30.2% and the clinical benefit rate was 54.7%. The median PFS was 6.89 months (95% CI 1.12 to 12.6 months) and OS was not reached. TBT being &lt; or &gt; the median impact on OS with HR 4.5 (95% CI 1.22 to 16.9; p = 0.024). Once again, there was a statistically significant difference in terms of PFS and OS when related to pooled TBT ≤ or &gt; 200 mm. The PFSm was 9.4 months (95% CI NR) for TBT ≤ 200 and 2.6 months ( 95% CI 1.9 to 3.2 months) to TBT &gt; 200, with a HR: 2.64 (95% CI 1.03 to 6.74; p = 0.042). OSm regarding TBT ≤ 200 was not reached and was 2.6 months (95% CI 2.0 to 3.2 months) to TBT &gt; 200, with RH:8.9 (95% CI 2.56 to 30.9; p = 0.001). According to the Fisher's exact test analysis, there is a significant association between LDH &gt; ULN and pooled TBT &gt; 200, with p = 0.023. Also, a relation between grouped TBT ( ≤ 200 or &gt; 200) and the type of response seemed to be significant, with p = 0.021. Conclusions: The results of our study are very consistent with current medical literature. In our study, high TBT was associated with less response rates and both less OS and PFS rates.
Diseases of the Kidneys and Bladder.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE RIGHT OF PHYSICIANS TO DEDUCT TRAVELING EXPENSES
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells
Authors: Lufeng Zheng, Qianqian Guo, Chenxi Xiang, Shijia Liu, Yuzhang Jiang, Lanlan Gao, Haiwei Ni, Ting Wang, Qiong Zhao, Hai Liu, Yingying Xing, Yaohui Wang, Xiaoman Li, Tao Xi
Journal: Journal of Hematology & Oncology (2019)

Abstract Background The expression of CYP4Z1 and the pseudogene CYP4Z2P has been shown to be specifically increased in breast cancer by our group and others. Additionally, we previously revealed the roles of the competitive endogenous RNA (ceRNA) network mediated by these genes (ceRNET_CC) in breast cancer angiogenesis, apoptosis, and tamoxifen resistance. However, the roles of ceRNET_CC in regulating the stemness of breast cancer cells and the mechanisms through which ceRNET_CC is regulated remain unclear. Methods Transcriptional factor six2, CYP4Z1-3′UTR, and CYP4Z2P-3′UTR were stably overexpressed or knocked down in breast cancer cells via lentivirus infection. ChIP-sequencing and RNA-sequencing analysis were performed to reveal the mechanism through which ceRNET_CC is regulated and the transcriptome change mediated by ceRNET_CC. Clinical samples were used to validate the correlation between six2 and ceRNET_CC. Finally, the effects of the six2/ceRNET_CC axis on the stemness of breast cancer cells and chemotherapy sensitivity were evaluated by in vitro and in vivo experiments. Results We revealed that ceRNET_CC promoted the stemness of breast cancer cells. Mechanistically, six2 activated ceRNET_CC by directly binding to their promoters, thus activating the downstream PI3K/Akt and ERK1/2 pathways. Finally, we demonstrated that the six2/ceRNET_CC axis was involved in chemoresistance. Conclusions Our results uncover the mechanism through which ceRNET_CC is regulated, identify novel roles for the six2/ceRNET_CC axis in regulating the stemness of breast cancer cells, and propose the possibility of targeting the six2/ceRNET_CC axis to inhibit breast cancer stem cell (CSC) traits.
Highlights
Journal: JAMA (2017)

Treatment Regimens for Major Depressive Disorder 132Fewer than one-third of patients with major depressive disorder (MDD) achieve remission with their fi rst antidepressant; most treatment guidelines recommend either switching to another antidepressant or adding a pharmacotherapeutic agent.Mohamed and colleagues conducted a randomized clinical trial of 1522 patients with MDD who had not responded to a course of antidepressant treatment, fi nding that augmentation with aripiprazole resulted in a modestly increased likelihood of remission compared with switching to bupropion monotherapy.In an Editorial, Fava suggests that evidence from this and other studies supports the use of aripiprazole for patients who have not responded to antidepressant therapies.
Prenatal HIV Testing and Antiretroviral Prophylaxis at an Urban Hospital—Atlanta, Georgia, 1997-2000
Journal: JAMA (2004)

Includes children with sickle cell disease and other hemoglobinopathies, anatomic asplenia, chronic diseases (e.g., chronic cardiac and pulmonary disease and diabetes), cerebrospinal fluid leak, human immunodeficiency virus infection and other immunocompromising conditions, immunosuppressive chemotherapy or long-term systemic corticosteroid use; children who have undergone solid organ transplantation 2 ; and children who either have received or will receive cochlear implants. 4All these children have been identified as being at either "high risk" or "presumed high risk" for severe invasive pneumoccocal disease. 5
Hazards of restrictive diets
Authors: T. J. Bassler
Journal: JAMA (1984)

<h3>To the Editor.—</h3> Recent comments by Pritikin<sup>1</sup>and others debate the safety of his diet for the general public. As a former member of Pritikin's advisory board, I can confirm several examples of clinical "improvement" of symptomatic cardiac patients in his program. However, it does not necessarily follow that his 10% fat, 10% protein diet is suitable for all. Four years ago we reported fatal "nutritional arrhythmia" among elite marathon runners.<sup>2</sup>These deaths were associated with the triad of "lowbody fat, high training mileage, and diet restriction." Several of the cases involved diets similar to the Pritikin diet. Of course, marathon runners who use tobacco have increased risk of ischemic heart disease (Table 1), but these are easy to recognize clinically. However, the autopsy did not explain some of the deaths among 14 elite marathon runners who did not smoke (Table 2). These men had become lean, almost
Physical Medicine and Rehabilitation
Authors: Dorothea Daniels Glass
Journal: JAMA (1986)

Comprehensive rehabilitation of persons with major disabilities presents a broad spectrum of therapeutic problems, because all aspects of the patient's life are affected. The goal of rehabilitation is to retrain patients to optimize their residual abilities and develop alternative techniques and devices to replace permanent losses. This is best managed by an interdisciplinary team approach, which is one of the hallmarks of rehabilitation. Effective group interaction requires that each member of the team be responsible not only for care related to his/her own discipline but also for the efforts of the group as a whole.<sup>1</sup> This ideal can be difficult to achieve, because effective channels for keeping professional staff aware of relevant developments across disciplines are limited. Articles about significant research in fields other than medicine, eg, biomedical engineering, are not often indexed in the medical literature. Both the technical vocabulary and state-of-the-art knowledge may present a major barrier